2. Summary of studies: all‐cause mortality.
| Study | Country | Design | Settings | Months of follow‐up | Proportion deaths | RR (95%CI) | |
| smear arm (n/N) | Xpert arm (n/N) | ||||||
| Churchyard 2015 | South Africa | cluster‐RCT | primary health clinics | 6 | 116/2332 (5.0%) | 91/2324 (3.9%) | 1.10 (0.75 to 1.62) |
| Cox 2014 | South Africa | cluster‐RCT | primary health clinic | 6 | 38/1003 (3.8%) | 33/983 (3.4%) | 0.89 (0.56 to 1.40) |
| Mupfumi 2014 | Zimbabwe | RCT | ART initiation centre | 3 | 17/172 (9.9%) | 11/182 (6.0%) | 0.61 (0.29 to 1.27) |
| Ngwira 2019 | Malawi | cluster‐RCT | primary health centres | 12 | 58/685 (8.9%) | 55/818 (7.8%) | 0.79 (0.59 to 1.06) |
| Theron 2014a | multiple | RCT | primary health clinics | 6 | 63/758 (6%) | 58/744 (8%) | 0.94 (0.67 to 1.32) |
| Yoon 2012 | Uganda | before/after | national referral hospital | 2 | 44/186 (24%) | 64/259 (25%) | 1.04 (0.75 to 1.46) |
CI: confidence interval RCT: randomized controlled trial RR: risk ratio ART: antiretroviral therapy for HIV
Ngwira 2019 reported estimates as incidence rate ratios (IRR) 0.78 (95% CI 0.58 to 1.06). We converted to RR, assuming 12 months of follow‐up.
All estimates are unadjusted, apart from Churchyard 2015, who reported imbalance due to a small number of large clusters.